Delafloxacin––A novel fluoroquinolone for the treatment of ciprofloxacin‐resistant Pseudomonas aeruginosa in patients with cystic fibrosis
Abstract Introduction Fluoroquinolone antibiotics, namely ciprofloxacin and levofloxacin, play an important role in treating infection in cystic fibrosis (CF) and ciprofloxacin remains the last widely used and orally available antipseudomonal agent. Recently, a new fluoroquinolone, delafloxacin, has...
Main Authors: | Beverley Cherie Millar, John McCaughan, Jacqueline C. Rendall, John E. Moore |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | The Clinical Respiratory Journal |
Subjects: | |
Online Access: | https://doi.org/10.1111/crj.13262 |
Similar Items
-
Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> in an In Vitro Cystic Fibrosis Sputum Model
by: Vaughn D. Craddock, et al.
Published: (2023-06-01) -
Delafloxacin-Capped Gold Nanoparticles (DFX-AuNPs): An Effective Antibacterial Nano-Formulation of Fluoroquinolone Antibiotic
by: Amr Selim Abu Lila, et al.
Published: (2022-08-01) -
Evaluation of Delafloxacin against a Burkholderia pseudomallei Efflux Mutant Panel
by: Sandra P. McCurdy, et al.
Published: (2022-10-01) -
Delafloxacin: design, development and potential place in therapy
by: Candel FJ, et al.
Published: (2017-03-01) -
Efflux Inhibition in Clinical Isolates of Pseudomonas Aeruginosa Using Sertraline for Ciprofloxacin Resistance Breakdown
by: ahmad sahabzamani, et al.
Published: (2022-08-01)